Research programme: protein tyrosine kinase inhibitor therapeutics - Nexus BioPharma

Drug Profile

Research programme: protein tyrosine kinase inhibitor therapeutics - Nexus BioPharma

Alternative Names: Fyn kinase inhibitor therapeutics - Nexus BioPharma; Obesity and diabetes therapeutics - Nexus BioPharma; Weight loss drug - Nexus BioPharma

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nexus BioPharma
  • Developer Albert Einstein College of Medicine; Nexus BioPharma
  • Class Antidementias; Antihyperglycaemics; Antineoplastics; Obesity therapies; Small molecules
  • Mechanism of Action Proto-oncogene protein c-fyn inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Obesity
  • Research Alzheimer's disease; Cancer; Type 2 diabetes mellitus

Most Recent Events

  • 27 Sep 2016 Preclinical trials in Obesity in USA (unspecified route)
  • 12 Sep 2016 Nexus BioPharma files International patent application for protein tyrosine kinase inhibitors
  • 20 Jun 2016 Early research in Obesity in USA (unspecified route) before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top